Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
31 March 2020 Budapest, Hungary and Basel, Switzerland – Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, and Gedeon Richter Plc., a major pharmaceutical company in Central Eastern Europe focused on women’s health, today announced that they have entered into an exclusive license agreement for Gedeon Richter to commercialize relugolix […]Read More
Richter announces the acquisition of Finox Holding
30 June 2016 Richter announces the acquisition of Finox Holding for a consideration of CHF190 million. Finox Holding, a Swiss based biotech company engaged in the development and commercialisation of innovative and cost effective products addressing female fertility. Finox Holding product BEMFOLA® is a biosimilar r-hFSH, which stimulates the ovaries in order to treat infertility. Richter obtains global rights […]Read More
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
DUBLIN, Ireland and BUDAPEST, Hungary – 9 May 2016, — Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids. The study included 157 patients, with 101 patients randomized to ulipristal acetate 5 and 10mg […]Read More
Full Results of PEARL IV Study presented at the European Society of Gynaecological Endoscopy (ESGE) congress confirms the efficacy of ulipristal acetate 5 mg for the long term management of uterine fibroids
Budapest, 12 October 2015 – Gedeon Richter Plc. (“Richter”) announces results of the PEARL IV study at ESGE. PEARL IV was a Phase III, randomized, double-blind, parallel group study investigating the efficacy and safety of repeated 3 months treatment courses of daily 5mg or 10mgᵃ ulipristal acetate (UPA) for the long-term management of symptomatic uterine fibroids, characterized by heavy bleeding.¹ […]Read More